Adlai Nortye Group Stock Forecast
NASDAQ: ANLHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 9, 9:41 AM ET
ANL analyst consensus
Consensus (7 analysts)
strong_buy
Avg. price target
$29.50+94.21%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 7 Wall Street analysts covering Adlai Nortye Group (2026-10-09), 7 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $29.50, with a high estimate of $49.00 and a low estimate of $20.00. The average target implies upside of 94.2% from the current price of $15.19.
The spread between the highest and lowest targets is 145.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for ANL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 7 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-09.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $20.00 | +31.67% |
| Average target | $29.50 | +94.21% |
| High target | $49.00 | +222.58% |